"Imides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing two acyl groups bound to NITROGEN.
| Descriptor ID |
D007094
|
| MeSH Number(s) |
D02.478
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imides".
Below are MeSH descriptors whose meaning is more specific than "Imides".
This graph shows the total number of publications written about "Imides" by people in this website by year, and whether "Imides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imides" by people in Profiles.
-
Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013 Apr 28; 13:211.
-
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res. 2011 Feb 15; 17(4):880-7.
-
An ultrafast study of phenyl azide: the direct observation of phenylnitrenium ion. Org Lett. 2007 Sep 27; 9(20):3973-6.
-
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
-
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
-
Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. Invest New Drugs. 1995; 13(3):249-52.
-
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol. 1992 Aug; 46(2):230-2.
-
Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov; 9(4):353-6.
-
In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun; 6(2):79-85.
-
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15; 47(4):1040-4.